B 007
Alternative Names: B-007Latest Information Update: 14 Aug 2024
Price :
$50 *
At a glance
- Originator Shanghai Pharmaceuticals Holding
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Membranous glomerulonephritis; Myasthenia gravis; Pemphigus
- Phase I Non-Hodgkin's lymphoma
Most Recent Events
- 30 Jul 2024 Phase-II/III clinical trials in Membranous glomerulonephritis in China (SC) (NCT06470191)
- 12 Jul 2024 Phase-II/III clinical trials in Pemphigus in China (SC) (NCT06454357)
- 01 Jul 2024 Phase-II/III clinical trials in Myasthenia gravis in China (SC) (NCT06447597, SPH-B007-303)